Scrying Biotech
Long only, biotech, micro-cap, small-cap

With Or Without You Cyclacel Is Going To Rise

I've watched this happen too many times now. A stock stagnates in the winter of investor apathy only to shoot up suddenly like the tendrils of a tulip in spring. By then of course, it's too late. Your inattention has cost you a fortune. But before I explain why this is the case with Cyclacel (CYCC) Pharmaceuticals allow me to give you two recent examples from my portfolio that illustrate why this phenomenon occurs in the first place.

Example 1: A Misunderstood Science Fosters Buyer Indecision - Sunshine Heart (SSH)

From April 23rd to July 1st, Sunshine Heart stagnated at just over $5.00 a share. During that time some of the best authors on Seeking Alpha...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details